Companies / Health Care
CRL
Charles River Laboratories
Life Sciences Tools & Services
Life Sciences Tools & ServicesAnalysis in progress
In progress
We are decoding this company's strategy and relationships
New analyses are published every weekday. Founding members get them first.
Business at a glance
Operating-health scores describe reported fundamentals on a 0–100 scale. They are not a rating of the stock. How they work
Operating health50
Growth24
Profitability11
Cash generation60
Balance sheet59
Dilution control98
Key ratios and five-year financials
Latest quarter revenue YoY (2026-09-26)-2.2%Revenue growth (FY)-0.9%Revenue CAGR (3y)0.3%Gross margin—Operating margin0.6%Net margin-3.6%Free cash flow margin12.9%R&D / revenue—Stock comp / revenue1.8%Net debt / operating cash flow2.61xCurrent ratio1.29Diluted share count change-4.0%
| Fiscal year ending | FY 2021-12 | FY 2022-12 | FY 2023-12 | FY 2024-12 | FY 2025-12 |
|---|---|---|---|---|---|
| Revenue | $3.5B | $4.0B | $4.1B | $4.0B | $4.0B |
| Operating income | $590M | $651M | $617M | $227M | $25M |
| Net income | $391M | $486M | $475M | $22M | -$144M |
| Operating cash flow | $761M | $620M | $684M | $735M | $738M |
| Capital expenditure | $229M | $325M | $319M | $233M | $219M |
| Free cash flow | $532M | $295M | $365M | $502M | $518M |
| Stock-based comp | $71M | $74M | $72M | $70M | $71M |
| Buybacks | $41M | $39M | $24M | $119M | $361M |
| Cash | $241M | $234M | $277M | $195M | $214M |
| Total debt | $2.7B | $2.7B | $2.6B | $2.2B | $2.1B |
| Equity | $2.5B | $3.0B | $3.6B | $3.5B | $3.2B |
StratGraph publishes general, impersonal research about public companies based on public filings. It is not investment advice, not a recommendation to buy, sell or hold any security, and not tailored to any reader's circumstances. Content may contain errors and may be partly generated with AI tools; verify against the original filings, which are linked. Authors may not trade securities discussed within the window set by our trading policy. Full disclaimer.